For example, a phase I dose‐escalation study with sibrotuzumab, an antibody to human FAP, in patients with advanced NSCLC, showed that sibrotuzumab explicitly binds to the tumor sites without apparent side effects.142, 169. Here, FAP is linked to non-small cell lung carcinoma.